Drug Guidance for Subsidy 06/02/2026 Complement inhibitors for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome The Ministry of Health’s Drug Advisory Committee has recommended: Eculizumab 300 mg concentra... See all × 06/02/2026 Complement inhibitors for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome The Ministry of Health’s Drug Advisory Committee has recommended: Eculizumab 300 mg concentrate for solution for infusion as monotherapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children. Funding status REculizumab 300 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026. REculizumab should be used in line with the additional clinical criteria listed in the Annex. NRMAF assistance does not apply to iptacopan or ravulizumab for treating PNH or aHUS.
Post Marketing Information PEM 06/08/2025 Healthcare professional’s guide to FABHALTA® (iptacopan) PMG 06/08/2025 A guide to treatment with FABHALTA® (iptacopan) PAC 06/08/2025 Patient safety card: Important safety information for patients taking FABHALTA®